Flash FinanceUS
Market open S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · PMV Pharmaceuticals, Inc. (PMVP)

PMV Pharma Q3 net loss widens to $34.4 million from $21.1 million

Mixed Impact 3 of 5 earnings

PMV Pharmaceuticals reported third-quarter 2026 results, with a net loss of $34.4 million, or $0.52 per share, compared with $21.1 million, or $0.40 per share, a year earlier. The increase was mainly a $12.8 million non-cash warrant liability charge tied to the August 2026 public offering, while operating expenses fell, and the company said its cash runway extends into the first quarter of 2028.

Key points

  • Net loss was $34.4 million for the quarter ended September 30, 2026, versus $21.1 million a year earlier; the increase was primarily a $12.8 million non-cash loss from the change in fair value of the warrant liability.
  • R&D expenses fell to $16.1 million from $18.2 million, and G&A expenses fell to $4.0 million from $4.3 million.
  • Cash, cash equivalents, and marketable securities were $108.5 million as of September 30, 2026, which the company said supports a cash runway into the first quarter of 2028.
  • The company plans to submit a New Drug Application for rezatapopt in platinum-resistant/refractory ovarian cancer in the first quarter of 2027.

The filing

CompanyPMV Pharmaceuticals, Inc. (PMVP)
Form8-K, current report
Filed with the SECNov 10, 2026, 8:00 AM ET
Accession number0001193125-26-454467

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 10, 2026, 8:23 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.